Vaccitech (NASDAQ:VACC) Stock Price Down 2.3%

Vaccitech plc (NASDAQ:VACC)’s stock price fell 2.3% on Wednesday . The stock traded as low as $1.27 and last traded at $1.29. 28,978 shares changed hands during trading, a decline of 88% from the average session volume of 244,643 shares. The stock had previously closed at $1.32.

Vaccitech Stock Performance

The company has a 50 day simple moving average of $1.53 and a two-hundred day simple moving average of $2.11. The company has a market cap of $49.53 million, a PE ratio of -0.90 and a beta of -0.40.

Hedge Funds Weigh In On Vaccitech

An institutional investor recently bought a new position in Vaccitech stock. M&G Plc purchased a new stake in Vaccitech plc (NASDAQ:VACC) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 5,197,349 shares of the company’s stock, valued at approximately $25,987,000. M&G Plc owned approximately 13.48% of Vaccitech as of its most recent filing with the SEC. Institutional investors own 26.13% of the company’s stock.

About Vaccitech

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.